Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Saxagliptin,Metformin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Saxagliptin and Metformin Hydrochloride extended-release tablets is a dipeptidyl peptidase-4 (DPP4) inhibitor and biguanide combination product indicated for adults with type 2 diabetes mellitus.
Product Name : Kombiglyze-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
October 08, 2023
Lead Product(s) : Saxagliptin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Saxagliptin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner with type 2 d...
Product Name : Saxagliptin-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
February 16, 2023
Lead Product(s) : Saxagliptin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable